135 related articles for article (PubMed ID: 9619361)
1. Update on the diagnosis and treatment of prostate cancer.
Small EJ
Curr Opin Oncol; 1998 May; 10(3):244-52. PubMed ID: 9619361
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer update: 2005.
Ryan CJ; Small EJ
Curr Opin Oncol; 2006 May; 18(3):284-8. PubMed ID: 16552242
[TBL] [Abstract][Full Text] [Related]
3. [Limitations on the interpretation of prostate-specific antigen serum levels].
Sciarra A; Casale P; Di Nicola S; Di Chiro C; Colella D; Di Silverio F
Minerva Urol Nefrol; 1999 Jun; 51(2):105-12. PubMed ID: 10429421
[TBL] [Abstract][Full Text] [Related]
4. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer.
Loberg RD; Fielhauer JR; Pienta BA; Dresden S; Christmas P; Kalikin LM; Olson KB; Pienta KJ
Urology; 2003 Dec; 62 Suppl 1():128-33. PubMed ID: 14747050
[TBL] [Abstract][Full Text] [Related]
6. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
7. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
Ryan CJ; Small EJ
Urology; 2003 Dec; 62 Suppl 1():87-94. PubMed ID: 14747046
[TBL] [Abstract][Full Text] [Related]
8. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Hellerstedt B
Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer diagnosed in spinal cord-injured patients is more commonly advanced stage than in able-bodied patients.
Scott PA; Perkash I; Mode D; Wolfe VA; Terris MK
Urology; 2004 Mar; 63(3):509-12. PubMed ID: 15028447
[TBL] [Abstract][Full Text] [Related]
10. [Neoadjuvant hormonal therapy for prostate cancer].
Miyakita H
Nihon Rinsho; 2005 Feb; 63(2):309-13. PubMed ID: 15714984
[TBL] [Abstract][Full Text] [Related]
11. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
12. Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer.
Dawson NA; Slovin SF
Urology; 2003 Dec; 62 Suppl 1():102-18. PubMed ID: 14747048
[TBL] [Abstract][Full Text] [Related]
13. [Clinics in prostate cancer].
Sugimura Y
Rinsho Byori; 2004 Jul; 52(7):604-10. PubMed ID: 15344560
[TBL] [Abstract][Full Text] [Related]
14. The patient with hormone-refractory prostate cancer: determining who, when, and how to treat.
Kent EC; Hussain MH
Urology; 2003 Dec; 62 Suppl 1():134-40. PubMed ID: 14747051
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of prostate cancer].
Romics I
Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076
[No Abstract] [Full Text] [Related]
16. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
17. Avoidance and management of positive surgical margins before, during and after radical prostatectomy.
Bott SR; Kirby RS
Prostate Cancer Prostatic Dis; 2002; 5(4):252-63. PubMed ID: 12627209
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K
Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750
[TBL] [Abstract][Full Text] [Related]
19. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
Pienta KJ;
Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
[TBL] [Abstract][Full Text] [Related]
20. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
